NSE: LUPIN · 22 October 2026
- Lupin Limited shares declined 2.14% on October 22, 2026, settling at ₹1,922.0 after opening the session lower at ₹1,942.0. The stock traded within a narrow intraday range, touching a high of ₹1,945.7 and a low of ₹1,930.0 before hitting a session low of ₹1,896.1, which also marked its new 52-week low.
- NSE Sustainability Ratings and Analytics Limited independently assigned Lupin Limited an Environmental, Social, and Governance score of 70 for fiscal year 2026, compared to 71 in the previous fiscal year. The marginal one-point dip was attributed to lower scores in the Social and Governance pillars.
- Trading volume was 1.07 times the 20-day average daily volume.
Why is LUPIN share price falling on 22 October 2026?
Lupin Limited shares declined 2.14% on October 22, 2026, settling at ₹1,922.0 after opening the session lower at ₹1,942.0. The stock traded within a narrow intraday range, touching a high of ₹1,945.7 and a low of ₹1,930.0 before hitting a session low of ₹1,896.1, which also marked its new 52-week low.
The broader market witnessed downward pressure during the session, as the benchmark Nifty fell 0.88%. In comparison, the Nifty Pharma sector index remained relatively resilient, edging down by just 0.07%. Lupin's negative performance outpaced the sectoral decline, reflecting continued short-term weakness that follows a 1.60% drop over the past 5 trading days and a 9.98% correction over the past 20 trading days.
7.29 lakh shares traded by 22 October 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 6.79 lakh shares (1.07 times). The five-day average daily volume was 6.87 lakh shares. Separately, the NSE report for 22 October 2026 showed 3.98 lakh shares delivered, representing 54.62% of that day’s traded volume. The same report recorded 35,962 trades.
The stock declined alongside a softer broader market, extending its recent 20-day downward trend. No new same-day operational trigger was reported, suggesting the move reflects ongoing profit-taking or positioning adjustments.
Latest Company Developments
NSE Sustainability Ratings and Analytics Limited independently assigned Lupin Limited an Environmental, Social, and Governance score of 70 for fiscal year 2026, compared to 71 in the previous fiscal year. The marginal one-point dip was attributed to lower scores in the Social and Governance pillars.
Provides investors with an independent benchmark of the company's non-financial and sustainability metrics.
Lupin announced that it received final approval from the U.S. FDA for its Abbreviated New Drug Application for Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL single-dose prefilled syringe. The approved product is bioequivalent to the reference listed drug indicated for the treatment of hypoprothrombinemia and vitamin K deficiency, with estimated annual U.S. sales of USD 52.3 million according to IQVIA data.
Expands Lupin's complex injectable portfolio in the regulated U.S. market, supporting future revenue opportunities.
a press release dated October 08, 2026, titled "Lupin Receives U.S. FDA Approval for Phytonadione Injectable Emulsion, USP".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 14.58% on 30 September 2026. This compares with 14.84% on 30 June 2026, a change of -0.26 percentage points.
The filing reported 43 MF/UTI holders.
Historical Bulk / Block Deals
Price Action | Lupin shares slip as Citi downgrades to sell; ICICI Pru AMC slips 3% on block deal. Price Action | Lupin shares slip as Citi downgrades to sell; ICICI Pru AMC slips 3% on block deal Moneycontrol.com
What to Watch Next
- Upcoming standalone and consolidated financial results scheduled for review by the Board of Directors on November 3, 2026
- Market execution and commercial uptake following the recent launch of Formoflo-G MDI in India
- Progress on commercializing newly approved U.S. pipeline products including Phytonadione Injectable Emulsion
- Delivery volume trends relative to the 20-day average volume baseline of 728,620 shares
Other Dated Coverage
- Lupin in Focus Today Following Independent FY26 ESG Rating Assignment | 16 October 2026 — 16 October 2026
- Lupin in Focus After Launching Formoflo-G MDI for COPD; What to Watch | 8 October 2026 — 8 October 2026
- LUPIN Share Price Today: Why LUPIN Is Falling 0.81% | 7 October 2026 — 7 October 2026
More LUPIN news and dated analysis →
Frequently Asked Questions
What is the latest LUPIN company news?
NSE Sustainability Ratings and Analytics Limited independently assigned Lupin Limited an Environmental, Social, and Governance score of 70 for fiscal year 2026, compared to 71 in the previous fiscal year. The marginal one-point dip was attributed to lower scores in the Social and Governance pillars.
How strong was LUPIN’s trading volume?
7.29 lakh shares traded, 1.07 times the 20-day average daily volume. The price and volume data are dated 22 October 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.